Drug equals tamoxifen in preventing breast cancer, fewer side-effects: study

From the Canadian Press:
An osteoporosis drug has been found to reduce the incidence of invasive breast cancer in high-risk, post-menopausal women as effectively as the current gold-standard drug tamoxifen - but with far fewer serious side-effects, researchers say.

In a head-to-head study sponsored by the U.S. National Cancer Institute (NCI), both raloxifene and tamoxifen were found to reduce the risk of invasive breast cancer by almost 50 per cent compared with a placebo. ...more